Use of Rifamycin Drugs and Development of Infection by Rifamycin-Resistant Strains of Clostridium difficile

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.00548-13PMID 23545528PMCID PMC3716149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rifaximin in the treatment of recurrent Clostridium difficile infection

  2013cited by this paper
• Clinical and Laboratory Standards Institute.

  2013cited by this paper
• Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile

  2011cited by this paper
• Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA)

  2011influential reference
• Rifaximin in the treatment of hepatic encephalopathy

  2011cited by this paper
• Rifaximin therapy for patients with irritable bowel syndrome without constipation.

  2011cited by this paper
• Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

  2010cited by this paper
• Pharmacotherapy for Hepatic Encephalopathy

  2010cited by this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cited by this paper
• In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas

  2010influential reference
• High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

  2009cited by this paper
• Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile

  2008cited by this paper
• Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

  2007cited by this paper
• In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004

  2007cited by this paper
• In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus

  2006cited by this paper
• Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria ; Approved Standard — Seventh Edition

  2003cited by this paper
• Detection of Nucleotide Variability in rpoB in both Rifampin-Sensitive and Rifampin-Resistant Strains of Chlamydia trachomatis

  2003cited by this paper
• Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.

  2001cited by this paper
• Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

  1993cited by this paper
• Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance.

  1988cited by this paper
• Drugs Five Years Later: Rifampin

  1976cited by this paper

• Efficacy and safety of rifaximin in preventing hepatic encephalopathy: A systematic review and meta-analysis

  2025cites this paper
• Molecular epidemiology and antimicrobial resistance in Clostridioides difficile strains isolated from children and adolescents in a tertiary referral pediatric hospital in Fortaleza, Brazil

  2024cites this paper
• Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis

  2023cites this paper
• Non-Toxin-Based Clostridioides difficile Vaccination Approaches

  2023cites this paper
• Characterization of Food Chain Clostridioides difficile Isolates in Terms of Ribotype and Antimicrobial Resistance

  2023cites this paper
• Gene network interaction analysis to elucidate the antimicrobial resistance mechanisms in the Clostridiumdifficile.

  2023cites this paper
• Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases

  2021cites this paper
• Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?

  2021cites this paper
• Rifamycin antibiotics and the mechanisms of their failure

  2021cites this paper
• Environmental risk assessment of antibiotics and AMR/ARGs

  2020cites this paper
• Antibiotika und der Gastrointestinaltrakt – Update 2019

  2019cites this paper
• Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry

  2019cites this paper
• Antimicrobial resistance in chronic liver disease

  2019cites this paper
• Antimicrobial resistance in Clostridium difficile ribotype 017

  2019cites this paper
• Characterisation of Clinical Clostridium difficile PCR Ribotype 002 Isolates from Different Time Lineages

  2019cites this paper
• Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin

  2018cites this paper
• Novel Antimicrobials for the Treatment of Clostridium difficile Infection

  2018cites this paper
• Neue Leitlinien und Daten zu Clostridium difficile – Was ändert sich?

  2018cites this paper
• Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial

  2018cites this paper
• Therapie akuter und rekurrenter Clostridium-difficile-Infektionen

  2018cites this paper
• Antibiotic Resistances of Clostridium difficile.

  2018cites this paper
• КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ НАЦИОНАЛЬНОЙ АССОЦИАЦИИ СПЕЦИАЛИСТОВ ПО КОНТРОЛЮ ИНФЕКЦИЙ, СВЯЗАННЫХ С ОКАЗАНИЕМ МЕДИЦИНСКОЙ ПОМОЩИ, И ОБЩЕРОССИЙСКОЙ ОБЩЕСТВЕННОЙ НЕКОММЕРЧЕСКОЙ ОРГАНИЗАЦИИ «АССОЦИАЦИЯ КОЛОПРОКТОЛОГОВ РОССИИ» ПО ДИАГНОСТИКЕ, ЛЕЧЕНИЮ И ПРОФИЛАКТИКЕ CLOSTRIDIUM DIFFICILE-АССОЦИИРОВАННОЙ ДИАР

  2018cites this paper
• The spread of antibiotic-resistant strains of Clostridioides difficile in patients with antibiotic-associated diarrhea

  2018cites this paper
• Conventional and alternative treatment approaches for Clostridium difficile infection

  2017cites this paper
• Innovative Approaches to Improve Anti-Infective Vaccine Efficacy.

  2017cites this paper
• Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden

  2016cites this paper
• Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection

  2016cites this paper
• Use of rifaximin in gastrointestinal and liver diseases.

  2016cites this paper
• Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome

  2016cites this paper
• Rifamycins, Alone and in Combination.

  2016cites this paper
• Therapies on the horizon for Clostridium difficile infections

  2016cites this paper
• Place and role of nonabsorbable antibiotics in the treatment of acute infectious diarrhea

  2015cites this paper
• Diagnosis and Management of Clostridium dif fi cile Infection

  2015cites this paper
• Using a Novel Lysin To Help Control Clostridium difficile Infections

  2015cites this paper
• Diagnosis and Management of Clostridium difficile Infection

  2015cites this paper
• Rifaximin: An Antibiotic with Important Biologic Effects.

  2015cites this paper
• The potential for emerging therapeutic options for Clostridium difficile infection

  2014cites this paper
• Progress in the Discovery of Treatments for C. difficile Infection: A Clinical and Medicinal Chemistry Review

  2013cites this paper
• Gaining of join resistance to metals and antibiotics in deep sea bacteria

  2013cites this paper